SLC5A2 and atrial fibrillation: Furthermore, a lower rate of AF and VT/VF was observed in the SGLT2-i users group compared with the non-users at Pearson Chi-Square test (4.5 vs. 9.5% and 1.8 vs. 6.2%, respectively; p = 0.032) (Figure 2).